Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Kyorin Pharmaceutical Co stock price, quote, forecast and news

4569.T
JP3247090008

Price

1,587.00
Today +/-
-0.21
Today %
-2.12 %
P

Kyorin Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kyorin Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kyorin Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kyorin Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kyorin Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kyorin Pharmaceutical Co Stock Price History

DateKyorin Pharmaceutical Co Price
9/4/20241,587.00 undefined
9/3/20241,621.00 undefined
9/2/20241,614.00 undefined
8/30/20241,624.00 undefined
8/29/20241,615.00 undefined
8/28/20241,634.00 undefined
8/27/20241,633.00 undefined
8/26/20241,618.00 undefined
8/23/20241,632.00 undefined
8/22/20241,621.00 undefined
8/21/20241,635.00 undefined
8/20/20241,631.00 undefined
8/19/20241,613.00 undefined
8/16/20241,630.00 undefined
8/15/20241,605.00 undefined
8/14/20241,610.00 undefined
8/13/20241,606.00 undefined
8/9/20241,597.00 undefined
8/8/20241,574.00 undefined

Kyorin Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kyorin Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kyorin Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kyorin Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kyorin Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kyorin Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kyorin Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kyorin Pharmaceutical Co’s growth potential.

Kyorin Pharmaceutical Co Revenue, EBIT and net profit per share

DateKyorin Pharmaceutical Co RevenueKyorin Pharmaceutical Co EBITKyorin Pharmaceutical Co Net Income
2027e125.28 B undefined0 undefined4.59 B undefined
2026e128.1 B undefined0 undefined5 B undefined
2025e126.48 B undefined0 undefined5.21 B undefined
2024119.53 B undefined6.01 B undefined5.32 B undefined
2023113.27 B undefined5.12 B undefined4.72 B undefined
2022105.53 B undefined5 B undefined3.93 B undefined
2021102.9 B undefined5.77 B undefined6.13 B undefined
2020109.98 B undefined7.49 B undefined6.15 B undefined
2019113.62 B undefined8.96 B undefined6.87 B undefined
2018110.64 B undefined8.81 B undefined6.57 B undefined
2017115.37 B undefined10.41 B undefined7.31 B undefined
2016119.48 B undefined19.64 B undefined13.64 B undefined
2015113.12 B undefined14.74 B undefined12.06 B undefined
2014111.4 B undefined17.61 B undefined12.03 B undefined
2013107.03 B undefined17.95 B undefined12.42 B undefined
2012103.23 B undefined14.46 B undefined9.23 B undefined
2011104.07 B undefined16.44 B undefined10.93 B undefined
201099.76 B undefined13.26 B undefined8.85 B undefined
200990.89 B undefined8.95 B undefined2.04 B undefined
200881.07 B undefined5.87 B undefined2.19 B undefined
200777.09 B undefined8.05 B undefined4.84 B undefined
2006366 M undefined143 M undefined20 M undefined
20053.38 B undefined-220 M undefined133 M undefined

Kyorin Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.180.230.29.823.380.3777.0981.0790.8999.76104.07103.23107.03111.4113.12119.48115.37110.64113.62109.98102.9105.53113.27119.53126.48128.1125.28
-27.78-11.304,715.20-65.61-89.1720,963.665.1612.119.764.32-0.803.684.081.545.62-3.44-4.102.69-3.20-6.442.567.335.535.811.28-2.20
52.7852.1755.3935.5736.23100.0059.8160.3559.5262.4363.9164.2362.5061.3658.8160.3655.9355.6550.5351.8650.1746.8544.2943.01---
0.10.120.113.491.220.3746.1148.9354.162.2966.5266.3166.968.3566.5272.1264.5361.5857.4157.0351.6349.4450.1751.41000
-0.09-0.04-0.050.21-0.220.148.055.878.9513.2616.4414.4617.9517.6114.7419.6410.418.818.967.495.7755.126.01000
-50.56-15.65-24.022.09-6.5139.0710.457.249.8513.2915.8014.0116.7715.8113.0316.439.037.967.886.815.614.744.525.02---
0.190.490.311.70.130.024.842.192.048.8510.939.2312.4212.0312.0613.647.316.576.876.156.133.934.725.325.2154.59
-158.64-37.45450.16-92.18-84.9624,110.00-54.79-6.94334.3623.50-15.5234.57-3.200.3213.06-46.44-10.014.49-10.48-0.31-35.8620.1212.68-2.10-4.13-8.07
---------------------------
---------------------------
747474747474757575757575757574.6474.0273.4673.6565.6257.2957.357.357.357.39000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Kyorin Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kyorin Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                               
0.170.360.44.790.1714.713.8612.8615.7225.5532.4928.9933.0448.9848.5251.748.6344.7232.5132.9230.8427.4919.3913.99
0.040.050.040.19026.731.4328.935.4836.7942.5345.0146.544.0746.9548.2546.1547.8252.5947.4140.4140.1245.4347.7
0000000000000000000001.521.820
0.060.070.081.75013.7714.6119.7718.1921.8720.3620.7419.9421.725.9327.6724.3823.3125.4233.2838.5742.2248.0353.4
0.01000.340.024.554.954.495.756.859.045.128.796.897.6710.877.124.14.393.454.215.034.364.16
0.290.480.527.060.1859.7264.8666.0175.1491.06104.4299.85108.27121.64129.06138.48126.27119.95114.9117.06114.03116.38119.03119.24
0.932.282.433.1021.3619.6418.2117.1215.8314.9214.5418.2120.8419.3722.7922.4321.921.7922.7223.924.3325.8328.95
5.345.535.5327.942.9428.6330.0730.6923.5323.7821.6626.0424.5523.831.0133.4640.6550.7229.825.8723.6525.722.9822.11
0020730916357302723241943024430000
0000.2704.632.51.360.680.470.480.650.851.21.181.21.21.753.43.333.793.295.395.09
0000.1401.091.6110.950.550.340.190.0600000000000
0.020.020.021.3105.835.295.067.15.475.394.373.011.892.751.892.122.423.132.181.772.222.812.24
6.297.84832.842.9461.6359.1856.3849.4146.1242.845.8246.747.7454.3259.3466.476.7958.1354.153.155.5557.0258.39
6.588.328.5239.93.13121.35124.03122.39124.55137.18147.23145.67154.97169.38183.38197.82192.67196.74173.03171.16167.13171.92176.05177.63
                                               
1414141414700700700700700700700700700700700700700700700700700700700
3.313.313.313.310.494.764.754.754.754.754.754.754.754.754.754.754.754.754.754.754.754.754.754.75
3.123.473.5329.021.3188.2691.5691.1392.3199.74106.93112.8121.86130.15137.58147.33150.3152.54129130.79132.56132.71134.4136.73
00000425637-159-134-232-266-179-885284-3,131-2,393-2,292-2,274-2,746-2,316-2,252-2,416-19
0.050.040.040.6201.181.20.75-0.850.14-0.140.542.293.437.807.6510.18.936.926.646.275.75.93
6.56.846.8932.971.8194.9498.2797.3796.75105.19112.01118.52129.42138.15151.11149.65161.01165.8141.1140.42142.33142.18143.13148.09
0.010.0101.5606.599.6910.798.269.8610.859.048.5611.0611.2611.7911.1610.2711.449.786.9910.913.7614.27
0000.0602.332.132.242.563.043.223.113.333.33.293.252.692.382.242.332.212.32.182.2
0.010.020.010.370.018.687.434.646.6910.449.318.039.2912.1611.6510.919.6111.266.618.487.558.368.438.73
01.40.131.50.130.770.691.534.152.496.72.861.181.371.131.230.630.1320.110.110.110.110.110.1
000000000.060.370.340.340.540.520.450.870.951.11.080.640.560.530.5110.2
0.021.430.153.490.1418.3719.9419.221.7126.1930.4223.3922.928.427.7728.0525.0325.1341.4831.3327.4132.1834.9845.49
001.422.281.171.130.81.131.130.640.460.360.180.260.280.540.480.413.0113.0511.4511.1810.840.44
0.040.030.030.0400000000002.822.612.071.262.060.20.290.1800.18
0.020.020.031.0806.355.124.885.25.444.643.732.792.93.929.577.256.643.093.873.323.884.760.79
0.060.051.483.41.177.485.926.016.336.085.14.092.973.167.0112.729.88.318.1617.1215.0615.2415.61.4
0.081.481.626.891.3125.8425.8625.2128.0532.2735.5227.4725.8731.5634.7840.7834.8333.4449.6448.4542.4747.4250.5846.89
6.588.328.5239.853.13120.78124.13122.58124.8137.47147.53145.99155.29169.7185.89190.43195.84199.24190.74188.87184.8189.6193.71194.98
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kyorin Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kyorin Pharmaceutical Co's financial health and stability.

Assets

Kyorin Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kyorin Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kyorin Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kyorin Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
2.680.050.028.265.624.8513.9817.1415.2618.618.3117.5618.829.729.069.368.268.355.226.91
-0.06-0.0104.784.794.113.212.672.512.873.223.053.733.623.642.943.223.563.713.84
00000000000000000000
-0.85-0.080.13-6.71-5.73-5.89-5.48-12.14-7.63-8.59-1.86-11.87-12.273.91-1.43-11.33-3.44-4.3-2.99-7.34
-2.42-2.170.01-1.32-0.243.040.31-0.86-1.23-1.34-0.38-2.350.87-0.86-0.82-0.63-0.36-2.430.41-1.48
694415333763635148211161729246475686666
0.860.1-0.023.084.572.51.987.016.514.626.094.644.53.771.663.481.511.91.252.07
-0.65-2.210.165.014.446.1112.036.818.9111.5419.296.3911.1416.3910.450.347.685.196.351.92
-981-730-3,644-2,151-1,581-1,252-1,500-2,043-6,316-3,095-5,855-7,342-2,645-3,873-4,369-3,217-5,124-2,690-9,405
0.81.530.22-3.14-6.14-4.230.41-1.81-4.93-7.19-2.48-1.360.65-13.14-6.0414.94-2.94-4.26-2.56-6.28
1.781.60.220.5-3.99-2.651.67-0.31-2.88-0.870.624.497.99-10.5-2.1719.310.270.870.133.13
00000000000000000000
-0.1-0.27-1.3-0.351.172.11-1.843.96-4.04-1.770.041.582.09-0.950.0718.59-0.77-0.57-0.34-0.35
0-1,500-4-47-90-65-33-21-12-2-1-2,186-458-445524-40,8390000
-0.24-2.02-0.12-2.63-1.531.19-3.290.2-7.41-5.13-3.7-5.23-2.25-5.72-3.74-27.32-5.12-4.92-4.11-3.36
001.2900000-0-0-00-0-000-0-0-0-0
-139-251-106-2,228-2,606-863-1,418-3,732-3,357-3,357-3,736-4,626-3,876-4,322-4,325-5,068-4,346-4,347-3,767-3,015
-0.09-2.70.26-0.74-3.242.769.25.11-3.45-0.6713.29-0.19.32-2.540.47-12.06-0.4-4.03-0.19-7.47
-1,626-2,2861601,3612,2924,52910,7745,3066,8705,22816,1985373,79513,7406,581-4,0284,461633,657-7,481
00000000000000000000

Kyorin Pharmaceutical Co stock margins

The Kyorin Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kyorin Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kyorin Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kyorin Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kyorin Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kyorin Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kyorin Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kyorin Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kyorin Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kyorin Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kyorin Pharmaceutical Co Margin History

Kyorin Pharmaceutical Co Gross marginKyorin Pharmaceutical Co Profit marginKyorin Pharmaceutical Co EBIT marginKyorin Pharmaceutical Co Profit margin
2027e43.01 %0 %3.67 %
2026e43.01 %0 %3.9 %
2025e43.01 %0 %4.12 %
202443.01 %5.02 %4.45 %
202344.29 %4.52 %4.17 %
202246.85 %4.74 %3.73 %
202150.17 %5.61 %5.96 %
202051.86 %6.81 %5.59 %
201950.53 %7.88 %6.05 %
201855.65 %7.96 %5.94 %
201755.93 %9.03 %6.33 %
201660.36 %16.43 %11.42 %
201558.81 %13.03 %10.66 %
201461.36 %15.81 %10.79 %
201362.5 %16.77 %11.61 %
201264.23 %14.01 %8.94 %
201163.91 %15.8 %10.5 %
201062.43 %13.29 %8.87 %
200959.52 %9.85 %2.24 %
200860.35 %7.24 %2.7 %
200759.81 %10.45 %6.28 %
2006100 %39.07 %5.46 %
200536.23 %-6.51 %3.94 %

Kyorin Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Kyorin Pharmaceutical Co earnings per share therefore indicates how much revenue Kyorin Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kyorin Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kyorin Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kyorin Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kyorin Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kyorin Pharmaceutical Co Revenue, EBIT and net profit per share

DateKyorin Pharmaceutical Co Sales per ShareKyorin Pharmaceutical Co EBIT per shareKyorin Pharmaceutical Co Earnings per Share
2027e2,180.77 undefined0 undefined79.94 undefined
2026e2,229.82 undefined0 undefined86.96 undefined
2025e2,201.59 undefined0 undefined90.7 undefined
20242,082.82 undefined104.64 undefined92.73 undefined
20231,976.68 undefined89.33 undefined82.42 undefined
20221,841.72 undefined87.31 undefined68.62 undefined
20211,795.88 undefined100.77 undefined106.98 undefined
20201,919.76 undefined130.7 undefined107.33 undefined
20191,731.49 undefined136.51 undefined104.68 undefined
20181,502.32 undefined119.59 undefined89.26 undefined
20171,570.58 undefined141.75 undefined99.44 undefined
20161,614.28 undefined265.29 undefined184.27 undefined
20151,515.58 undefined197.44 undefined161.63 undefined
20141,485.33 undefined234.76 undefined160.33 undefined
20131,427.08 undefined239.31 undefined165.63 undefined
20121,376.43 undefined192.85 undefined123.08 undefined
20111,387.59 undefined219.25 undefined145.69 undefined
20101,330.19 undefined176.83 undefined117.97 undefined
20091,211.85 undefined119.36 undefined27.16 undefined
20081,080.93 undefined78.23 undefined29.19 undefined
20071,027.91 undefined107.39 undefined64.56 undefined
20064.95 undefined1.93 undefined0.27 undefined
200545.65 undefined-2.97 undefined1.8 undefined

Kyorin Pharmaceutical Co business model

Kyorin Holdings Inc is a Japanese holding company that was founded in September 2007. However, the company's history dates back to 1947 when Kyorin Pharmaceutical Co., Ltd. was established. Kyorin Holdings is a diversified company that operates in various sectors and business areas. The company's main activities include the development, production, and marketing of pharmaceutical products, medical devices, and healthcare products. In the pharmaceutical sector, Kyorin has been active since its inception. The company offers a wide range of products for various conditions such as asthma, allergies, or diabetes. Additionally, Kyorin is dedicated to developing medications for rarer diseases such as Fabry disease or amyotrophic lateral sclerosis (ALS). Another important business area of Kyorin is medical devices and accessories. The company primarily focuses on devices for the diagnosis and treatment of respiratory diseases and allergies. This includes inhalers, peak flow meters, and allergy tests. Healthcare is another significant business area of Kyorin Holdings. The company offers products for maintaining and strengthening the immune system, such as dietary supplements and probiotics. Kyorin also provides cosmetic products made from plant-based ingredients. One of Kyorin's current projects is the development of peptide-based immunotherapies for cancer. The company has already achieved promising results in preclinical research and plans to continue clinical trials in the coming years. The corporate philosophy of Kyorin emphasizes the importance of research and development. The company invests a significant portion of its annual revenue in research and development and strives to find innovative solutions for disease treatment. Kyorin also values collaboration with other companies and research institutions. The company has formed partnerships with other pharmaceutical and medical technology companies to work together on the research and development of new products. Kyorin Holdings Inc is a company that focuses on the development and marketing of products that contribute to improving health and well-being. The company's various business areas allow it to target different audiences and meet the needs of patients and customers in various fields. With its long-standing experience in the pharmaceutical and medical technology sectors and its commitment to innovation and research, Kyorin remains an important player in healthcare and is dedicated to improving the quality of life for people worldwide. Kyorin Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Kyorin Pharmaceutical Co SWOT Analysis

Strengths

Kyorin Holdings Inc possesses several strengths that contribute to its success in the market:

  • Strong brand reputation and recognition in the pharmaceutical industry.
  • Diverse portfolio of products, including both prescription and over-the-counter drugs.
  • Robust distribution network, enabling wide geographic coverage.
  • Strong financial position and solid revenue growth.
  • Effective research and development capabilities, allowing for continuous innovation.

Despite its strengths, there are some areas where Kyorin Holdings Inc could improve:

  • Limited global presence compared to some of its competitors.
  • Relatively higher production costs affecting profitability.
  • Dependency on a few key products for a significant portion of its revenue.

Kyorin Holdings Inc can take advantage of the following opportunities in the market:

  • Expanding into emerging markets with growing healthcare needs.
  • Increasing demand for personalized medicine and targeted therapies.
  • Growing interest in alternative and complementary medicine products.
  • Potential partnerships or acquisitions to strengthen its product portfolio and market presence.

Several external factors pose threats to Kyorin Holdings Inc's business:

  • Intense competition from local and international pharmaceutical companies.
  • Regulatory challenges and changing government policies impacting market access.
  • Increasing pressure to reduce drug prices and healthcare costs.
  • Potential risks associated with product safety and quality.

Weaknesses

Despite its strengths, there are some areas where Kyorin Holdings Inc could improve:

  • Limited global presence compared to some of its competitors.
  • Relatively higher production costs affecting profitability.
  • Dependency on a few key products for a significant portion of its revenue.

Kyorin Holdings Inc can take advantage of the following opportunities in the market:

  • Expanding into emerging markets with growing healthcare needs.
  • Increasing demand for personalized medicine and targeted therapies.
  • Growing interest in alternative and complementary medicine products.
  • Potential partnerships or acquisitions to strengthen its product portfolio and market presence.

Several external factors pose threats to Kyorin Holdings Inc's business:

  • Intense competition from local and international pharmaceutical companies.
  • Regulatory challenges and changing government policies impacting market access.
  • Increasing pressure to reduce drug prices and healthcare costs.
  • Potential risks associated with product safety and quality.

Opportunities

Kyorin Holdings Inc can take advantage of the following opportunities in the market:

  • Expanding into emerging markets with growing healthcare needs.
  • Increasing demand for personalized medicine and targeted therapies.
  • Growing interest in alternative and complementary medicine products.
  • Potential partnerships or acquisitions to strengthen its product portfolio and market presence.

Several external factors pose threats to Kyorin Holdings Inc's business:

  • Intense competition from local and international pharmaceutical companies.
  • Regulatory challenges and changing government policies impacting market access.
  • Increasing pressure to reduce drug prices and healthcare costs.
  • Potential risks associated with product safety and quality.

Threats

Several external factors pose threats to Kyorin Holdings Inc's business:

  • Intense competition from local and international pharmaceutical companies.
  • Regulatory challenges and changing government policies impacting market access.
  • Increasing pressure to reduce drug prices and healthcare costs.
  • Potential risks associated with product safety and quality.

Kyorin Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kyorin Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Kyorin Pharmaceutical Co shares outstanding

The number of shares was Kyorin Pharmaceutical Co in 2023 — This indicates how many shares 57.303 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kyorin Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kyorin Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kyorin Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kyorin Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kyorin Pharmaceutical Co Stock splits

In Kyorin Pharmaceutical Co's history, there have been no stock splits.

Kyorin Pharmaceutical Co dividend history and estimates

In 2023, Kyorin Pharmaceutical Co paid a dividend amounting to 52 JPY. Dividend means that Kyorin Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Kyorin Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Kyorin Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Kyorin Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Kyorin Pharmaceutical Co Dividend History

DateKyorin Pharmaceutical Co Dividend
2027e52.5 undefined
2026e52.5 undefined
2025e52.48 undefined
202452 undefined
202352 undefined
202252 undefined
202165 undefined
202075 undefined
201975 undefined
201868 undefined
201758 undefined
201658 undefined
201552 undefined
201462 undefined
201350 undefined
201245 undefined
201145 undefined
201050 undefined
200919 undefined
200811.5 undefined
200735 undefined
200630 undefined

Kyorin Pharmaceutical Co dividend payout ratio

In 2023, Kyorin Pharmaceutical Co had a payout ratio of 68.8%. The payout ratio indicates the percentage of the company's profits that Kyorin Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Kyorin Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Kyorin Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Kyorin Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Kyorin Pharmaceutical Co Payout Ratio History

DateKyorin Pharmaceutical Co Payout ratio
2027e69.62 %
2026e69.42 %
2025e71.01 %
202468.45 %
202368.8 %
202275.78 %
202160.75 %
202069.87 %
201971.65 %
201876.18 %
201758.32 %
201631.48 %
201532.17 %
201438.67 %
201330.19 %
201236.56 %
201130.89 %
201042.38 %
200969.96 %
200839.41 %
200754.21 %
200611,111.11 %
200568.8 %
Unfortunately, there are currently no price targets and forecasts available for Kyorin Pharmaceutical Co.

Kyorin Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/201479.79 81.32  (1.92 %)2015 Q3
3/31/201437.88 36.85  (-2.72 %)2014 Q4
12/31/201366.26 65.26  (-1.5 %)2014 Q3
9/30/201318.89 18.74  (-0.78 %)2014 Q2
6/30/201337.88 40.11  (5.9 %)2014 Q1
12/31/201263.53 66.48  (4.65 %)2013 Q3
9/30/201218.89 19.49  (3.19 %)2013 Q2
12/31/201154.04 51.82  (-4.1 %)2012 Q3
9/30/201114.95 8.8  (-41.13 %)2012 Q2
12/31/201064.24 61.24  (-4.66 %)2011 Q3
1
2

Kyorin Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
8.60 % Mykam Co.4,943,384100,3842/8/2024
7.01 % Kopernik Global Investors, LLC4,026,400659,4006/15/2023
4.90 % Lucius Co., Ltd.2,817,6002,817,6002/8/2024
3.86 % KYORIN Pharmaceutical Co., Ltd. Group Company2,219,000-10,0009/30/2023
3.39 % KK Banrina1,950,00002/8/2024
3.39 % KK Achanzu1,950,00002/8/2024
3.06 % Ogiwara (Mariko)1,760,00009/30/2023
2.79 % Kaken Pharmaceutical Co Ltd1,602,00009/30/2023
2.35 % The Vanguard Group, Inc.1,349,608-6,9003/31/2024
2.22 % Nomura Asset Management Co., Ltd.1,277,1448,6003/31/2024
1
2
3
4
5
...
10

Kyorin Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Nichi-iko Pharmaceutical Stock
Nichi-iko Pharmaceutical
SupplierCustomer0,840,920,810,710,300,83
Suzuken Stock
Suzuken
SupplierCustomer0,820,940,700,530,390,73
Medipal Holdings Stock
Medipal Holdings
SupplierCustomer0,760,870,820,690,490,04
Toho Stock
Toho
SupplierCustomer0,750,90-0,220,110,360,72
Nisshin Seifun Group Stock
Nisshin Seifun Group
SupplierCustomer0,730,810,540,360,31-0,04
Medical Ikkou Group Stock
Medical Ikkou Group
SupplierCustomer0,720,17-0,16-0,37-0,28-
ASKA Pharmaceutical Stock
ASKA Pharmaceutical
SupplierCustomer0,620,960,350,350,370,51
Alfresa Holdings Stock
Alfresa Holdings
SupplierCustomer0,620,730,680,440,500,88
Resona Stock
Resona
SupplierCustomer0,510,870,470,540,36-0,52
Teijin Stock
Teijin
SupplierCustomer0,500,810,370,35-0,100,43
1
2
3

Most common questions regarding Kyorin Pharmaceutical Co

What values and corporate philosophy does Kyorin Pharmaceutical Co represent?

Kyorin Holdings Inc represents values of integrity, innovation, and patient-centric approach. With a dedicated corporate philosophy, the company strives to contribute to improving the quality of life and healthcare services. Kyorin Holdings Inc prioritizes ethical business practices, ensuring transparency and trustworthiness in all its operations. Through continuous research and development, the company aims to deliver cutting-edge pharmaceutical and healthcare solutions. With a focus on patient well-being, Kyorin Holdings Inc fosters collaborations and partnerships to enhance medical advancements and positively impact society.

In which countries and regions is Kyorin Pharmaceutical Co primarily present?

Kyorin Holdings Inc is primarily present in Japan.

What significant milestones has the company Kyorin Pharmaceutical Co achieved?

Kyorin Holdings Inc, a renowned company in the stock market, has achieved significant milestones throughout its history. With a strong commitment to excellence, Kyorin Holdings Inc has successfully expanded its portfolio and established a solid presence in various sectors. Notably, the company has achieved remarkable growth in the pharmaceutical industry, introducing innovative drugs and improving healthcare services. By leveraging its expertise and strategic partnerships, Kyorin Holdings Inc has consistently delivered impressive financial results, enhancing shareholder value and solidifying its position as a market leader. Through its continuous efforts in research and development, Kyorin Holdings Inc stands as a testament to its unwavering dedication to progress and success.

What is the history and background of the company Kyorin Pharmaceutical Co?

Kyorin Holdings Inc is a renowned Japanese pharmaceutical company with a rich history and solid background. Established in 1947, Kyorin Holdings Inc has been at the forefront of medical innovation, delivering high-quality healthcare products and services to customers worldwide. With a focus on research and development, Kyorin Holdings Inc has earned a stellar reputation in the industry for its dedication to advancing medical solutions. Over the years, the company has expanded its portfolio to include a diverse range of therapeutic areas, ranging from respiratory products to antiallergic medications. Kyorin Holdings Inc continues to strive for excellence in the healthcare sector, driven by its commitment to improving the well-being and quality of life for patients globally.

Who are the main competitors of Kyorin Pharmaceutical Co in the market?

Kyorin Holdings Inc faces competition from various companies in the market. Some of the main competitors of Kyorin Holdings Inc include Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, and Daiichi Sankyo Company, Limited. These companies operate in the same industry and offer similar products and services. However, Kyorin Holdings Inc has its unique strengths and is known for its innovative approach, superior quality, and strong customer base. With its strong presence and strategic initiatives, Kyorin Holdings Inc continues to thrive in the competitive market, ensuring sustainable growth and delivering value to its stakeholders.

In which industries is Kyorin Pharmaceutical Co primarily active?

Kyorin Holdings Inc is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Kyorin Pharmaceutical Co?

Kyorin Holdings Inc, a leading pharmaceutical company based in Japan, primarily focuses on the research, development, manufacturing, and sales of pharmaceutical products. Their business model entails a comprehensive approach that spans across the entire pharmaceutical value chain. Kyorin Holdings Inc leverages its expertise to deliver innovative and high-quality drugs, targeting various medical areas such as respiratory diseases, allergies, infectious diseases, and more. By combining advanced research and development capabilities with a strong sales and marketing network, Kyorin Holdings Inc strives to enhance people's health and well-being through the provision of effective and safe pharmaceutical solutions.

What is the P/E ratio of Kyorin Pharmaceutical Co 2024?

The Kyorin Pharmaceutical Co P/E ratio is 17.11.

What is the P/S ratio of Kyorin Pharmaceutical Co 2024?

The Kyorin Pharmaceutical Co P/S ratio is 0.76.

What is the AlleAktien quality score of Kyorin Pharmaceutical Co?

The AlleAktien quality score for Kyorin Pharmaceutical Co is 4/10.

What is the revenue of Kyorin Pharmaceutical Co 2024?

The Kyorin Pharmaceutical Co revenue is 119.53 B JPY.

How high is the profit of Kyorin Pharmaceutical Co 2024?

The Kyorin Pharmaceutical Co profit is 5.32 B JPY.

What is the business model of Kyorin Pharmaceutical Co

Kyorin Holdings Inc. is a Japanese company that operates in various business sectors. The company was founded in 1950 and is headquartered in Tokyo, Japan. Kyorin Holdings Inc. is listed on the Tokyo Stock Exchange and also operates internationally. The company operates in three main business areas: pharmaceuticals, life science, and investment. In the pharmaceutical business sector, the company develops and distributes a wide range of prescription and over-the-counter drugs. Kyorin Holdings Inc. has its own production facility in Kashima, Japan, where these products are manufactured. The company focuses on cardiovascular, respiratory, urology, dermatology, and allergy areas. Some of the well-known products include the respiratory medication Eucrisa and the heart medication Inderal. In the life science sector, Kyorin Holdings Inc. operates a wide range of biotechnology and diagnostic companies. The company invests heavily in research and development to develop innovative products and technologies. Some of the well-known brands include the biotechnology company Kainos Medicine and the diagnostics company Paraxel. Kyorin Holdings Inc. also invests in other companies and operates an investment business sector. The company operates globally and focuses on various industries such as biotechnology, IT, financial services, and real estate. Kyorin Holdings Inc. also has a subsidiary called Kyorin Venture Capital, which specializes in supporting startups and their financing. To understand Kyorin Holdings Inc.'s business model, it is important to understand that the company has a diversified portfolio focusing on three main business areas. The company strives to be a leading provider in each of its sectors and to grow through research and development. Kyorin Holdings Inc. also has a clear growth strategy, focusing on global expansion and tapping into new markets. The company builds partnerships with other pharmaceutical and biotech companies to expand its market-leading position. Conclusion: Kyorin Holdings Inc.'s business model is focused on being a leading provider of pharmaceuticals, biotechnology products, and investment services. The company aims to continuously grow through research and development and expand into new markets through partnerships and strategic investments.

What is the Kyorin Pharmaceutical Co dividend?

Kyorin Pharmaceutical Co pays a dividend of 52 JPY distributed over payouts per year.

How often does Kyorin Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Kyorin Pharmaceutical Co or the company does not pay out a dividend.

What is the Kyorin Pharmaceutical Co ISIN?

The ISIN of Kyorin Pharmaceutical Co is JP3247090008.

What is the Kyorin Pharmaceutical Co ticker?

The ticker of Kyorin Pharmaceutical Co is 4569.T.

How much dividend does Kyorin Pharmaceutical Co pay?

Over the past 12 months, Kyorin Pharmaceutical Co paid a dividend of 52 JPY . This corresponds to a dividend yield of about 3.28 %. For the coming 12 months, Kyorin Pharmaceutical Co is expected to pay a dividend of 52.48 JPY.

What is the dividend yield of Kyorin Pharmaceutical Co?

The current dividend yield of Kyorin Pharmaceutical Co is 3.28 %.

When does Kyorin Pharmaceutical Co pay dividends?

Kyorin Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Kyorin Pharmaceutical Co?

Kyorin Pharmaceutical Co paid dividends every year for the past 22 years.

What is the dividend of Kyorin Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 52.48 JPY are expected. This corresponds to a dividend yield of 3.31 %.

In which sector is Kyorin Pharmaceutical Co located?

Kyorin Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kyorin Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kyorin Pharmaceutical Co from 12/1/2024 amounting to 20 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Kyorin Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Kyorin Pharmaceutical Co in the year 2023?

In the year 2023, Kyorin Pharmaceutical Co distributed 52 JPY as dividends.

In which currency does Kyorin Pharmaceutical Co pay out the dividend?

The dividends of Kyorin Pharmaceutical Co are distributed in JPY.

All fundamentals about Kyorin Pharmaceutical Co

Our stock analysis for Kyorin Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyorin Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.